Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

To overcome the unfavorable outcome of refractory/relapsed (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and conduct allogeneic stem cell transplantation (allo-SCT) safely, we designed a sequential therapy involving a single cycle of Inotuzumab ozogamicin (InO) and Bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Tomoaki, Fukushima, Kentaro, Kusakabe, Shinsuke, Yoshida, Koki, Suga, Makiko, Nakai, Ritsuko, Koike, Midori, Hino, Akihisa, Akuta, Keigo, Toda, Jun, Nagate, Yasuhiro, Doi, Yukiko, Fujita, Jiro, Yokota, Takafumi, Hosen, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866140/
https://www.ncbi.nlm.nih.gov/pubmed/35242526
http://dx.doi.org/10.1016/j.lrr.2022.100294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866140/
https://www.ncbi.nlm.nih.gov/pubmed/35242526
http://dx.doi.org/10.1016/j.lrr.2022.100294

Ejemplares similares